TransThera Sciences Nanjing, Inc. (the "TransThera") announced that the new drug application for Tinengotinib tablets has been accepted by the Center for Drug Evaluation ("CDE")of the National Medical ...
TipRanks on MSN
TransThera’s tinengotinib NDA for advanced cholangiocarcinoma accepted by China’s drug regulator
TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) has provided an announcement.
NANJING, China and GAITHERSBURG, Md., Dec. 18, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that the new drug application for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback